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Background: While the frequency and importance of antipsychotic switching in patients with schizophrenia, there
is insufficient evidence with regard to switching strategy. Quetiapine is one of the drugs of choice for switch
because of its unique receptor profile. However, there were no data on the long-term clinical and neurocognitive
effect of quetiapine in patients who had responded inadequately to prior antipsychotics. The purpose of this study
is to examine the long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched
from other antipsychotics because of inadequate therapeutic response. We hypothesized that quetiapine would
show long-term effectiveness in broad symptom dimensions including negative and neurocognitive symptoms
while having good tolerability.
Methods: Twenty-nine subjects with schizophrenia who did not respond to their current monotherapy of
antipsychotic or who could not tolerate the treatment were switched to quetiapine and assessed at baseline and at
3, 6, and 12 months. The outcome measures included the brief assessment of cognition in schizophrenia (BACS),
the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impressions Scale (CGI), the Schizophrenia
Quality of Life Scale Japanese version (JSQLS), the Athens Insomnia Scale (AIS), and the Drug Attitude Inventory
with 30 items (DAI-30). The Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS), HbA1c, prolactin (PRL), and
body weight were also evaluated.
Results: Statistically significant improvements were observed in all subscores of the PANSS, the GAF, and the
symptoms and side effects subscale of the JSQLS, the DIEPSS, the AIS, and the PRL level, and nearly significant
improvements were observed in the DAI-30. Quetiapine monotherapy was associated with significant improvement
in the verbal memory test, even after controlling for the practice effect. Although quetiapine was well tolerated,
three subjects dropped out because of the worsening of the psychotic symptoms and two additional subjects
dropped out because of somnolence.
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Conclusion: In this open-label, single-arm study of 29 patients, quetiapine improved both the clinical symptoms
and the neurocognitive impairment in chronic schizophrenia patients who failed to respond to prior antipsychotic
treatment.
Keywords: Schizophrenia, Quetiapine, Switching, Antipsychotic, Negative symptom, Cognitive impairment,
Treatment resistanceBackground
The antipsychotic medications have been a fundamental
part of the treatment of schizophrenia. Although the
benefit of antipsychotic treatment is evident especially
about the psychotic symptoms, inadequate therapeutic
response is common in this disorder [1,2]. If a patient
does not respond well to the administered antipsychotic,
and if the possibility of misdiagnosis or non-compliance
is excluded, a switch of the currently prescribed anti-
psychotic is an often employed step [3]. In fact, it is esti-
mated that switching because of suboptimal antipsychotic
efficacy or tolerability occurs in 30%–50% of patients a
year in outpatient clinic [4].
Although little is known about the optimal clinical
strategies for switching, it seems to be rational to choose
a new compound with a different receptor binding pro-
file [3]. From this point of view, quetiapine is one of the
strong candidates for some patients because of its unique
receptor profile. Quetiapine demonstrates a relatively high
affinity for the 5HT2A receptor and relatively low affinity
for the D2 receptor [5]. Such a low affinity for the D2
receptor is thought to be appropriate if the first com-
pound was characterized by high affinities to dopamine
receptors such as risperidone or first-generation anti-
psychotic (FGA) [3]. Furthermore, the high 5HT2A/D2
ratio leads to an overall increase in dopaminergic ac-
tivity in the prefrontal cortex, and enhanced prefrontal
activity is shown to be associated with the alleviation
of negative symptoms and the improvement of cogni-
tive function [6]. It is also important because the cog-
nitive and negative symptoms are often refractory to
antipsychotic treatment [7,8] and become the cause of
inadequate response. Collectively, this evidence sug-
gests that a study examining the long-term efficacy of
quetiapine on negative as well as cognitive symptoms
after switching from other antipsychotics might be
quite valuable.
There were several studies that examined the long-term
efficacy and tolerability of the quetiapine comparing with
placebo [9] or risperidone [10-13]. Although the difference
in the modes of dosage should be noted (oral risperidone
[10,11] and risperidone long-acting injection [12,13], oral
quetiapine immediate [11] and extended release [9,12]), in
general, quetiapine showed long-term effectiveness similar
to [11] or less than risperidone [10], a positive relapseprevention effect better than placebo [9] and equal to ris-
peridone [12] except for its ability to achieve remission,
which was less than risperidone [12,13]. When focused on
studies that switched over to quetiapine, Larmo and his
colleagues (2005) showed significant improvement in the
Positive and Negative Syndrome Scale (PANSS) positive,
negative, and general psychopathology subscales after
switching to quetiapine in patients who were previ-
ously treated with low-dose haloperidol, risperidone,
or olanzapine [14]. Recently, Chue et al. (2013) reported
another open-label, prospective study to evaluate long-
term clinical benefits of switching to quetiapine extended
release from an oral antipsychotic in patients with schizo-
phrenia. In this study, majority of the subjects switching
from other antipsychotics to quetiapine due to insufficient
efficacy or insufficient tolerability showed clinical benefits
[15]. In all of these studies, quetiapine showed good long-
term tolerability with little extrapyramidal side effects and
hyperprolactinemia [10,14], and most common adverse
events were somnolence and dizziness [11-15].
With regard to pharmacological treatment of the cogni-
tive impairment, recent large sample naturalistic studies
showed that the magnitude of cognitive improvement
does not differ between first- and second-generation anti-
psychotics or between any two second-generation antipsy-
chotics, if the dose of first-generation antipsychotics were
appropriate [16-18]. However, in a randomized, double-
blind 52-week comparison on neurocognitive function in
early psychosis, quetiapine showed greater improvement
than both olanzapine and risperidone on measures of ver-
bal fluency and digit symbol coding test and than olanza-
pine on continuous performance test at Week 12 [19].
The superiority of quetiapine compared to other second-
generation antipsychotics were also shown in a recent
meta-analysis of two double-blind and one open-label
studies [20]. However, there has been no data on the long-
term neurocognitive effects of quetiapine in patients who
had responded inadequately to prior antipsychotics.
In this study, we examined the long-term efficacy and
tolerability of quetiapine in patients with schizophrenia
who switched from other antipsychotics because of inad-
equate therapeutic response. We hypothesized that que-
tiapine would show long-term improvement in broad
symptom dimensions including negative and neurocog-
nitive symptoms while having good tolerability.
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Participants
This is a prospective, open-label study. The eligible sub-
jects were schizophrenia patients aged 20 years or more,
who need switch of antipsychotic because of an inad-
equate response (cognitive impairment, negative, positive,
or general psychopathology symptoms) or intolerance for
their current antipsychotic medication. The diagnosis ac-
cording to the DSM-IV-TR and judgment about an inad-
equate response and/or poor tolerability were made by
treating psychiatrists, who had at least 6 years of clinical
experience. These eligible criteria are in consistent with
the SPECTRUM trial [14]. Patients who had a history of
seizure disorder, dementia, diabetes mellitus, history of
substance misuse including alcohol abuse, or other signifi-
cant laboratory results were excluded from the study. The
subjects who were currently suicidal and women who
were pregnant or breastfeeding were also excluded.
The study was conducted between January 2008 and
December 2012 at nine clinical sites in Hokkaido, Japan
(one university hospital, three general hospital, and five
psychiatric hospitals). This study was approved by the
ethics committees at Hokkaido University Hospital and
has been carried out in accordance with the Declaration
of Helsinki. We provided detailed explanations regarding
the study procedures and the potential risk and benefits
of pharmacotherapy to the eligible subjects. All partici-
pants voluntarily provided their written informed consent.
Procedure
The trial began with a cross-titration period of 1 month
to allow a gradual transition, followed by an 11-month
follow-up phase during which quetiapine could be flex-
ibly dosed. During the cross-titration period, a dose of
quetiapine was titrated at a target dose of 400 mg/day,
while the previous antipsychotic was gradually discontin-
ued. During the follow-up period, the maximum dose of
quetiapine was 750 mg/day. The concomitant use of
psychotropics, such as anxiolytics, mood stabilizers, and
antidepressants, was permitted, and the daily dosages of
all psychotropics were recorded throughout the study.
Hypnotics were tapered off if possible after the assess-
ment at 6 months. The concomitant use of drugs for par-
kinsonism, which included anticholinergic agents, was
permitted for the first 3 months, and it was also tapered
off after the assessment at 3 months; continuous use was
permitted if necessary. Non-psychoactive medications for
stable conditions that were already taken by the subject
before entry into the study were allowed to continue.
Clinical assessments
The assessments were performed at four points (base-
line and 3, 6, and 12 months after entry). The baseline
assessment had been done before cross-titration. Clinicalimprovement was examined using the Global Assessment
of Functioning (GAF) and the PANSS [21]. Quality of life
was assessed by the Schizophrenia Quality of Life Scale
Japanese version (JSQLS) [22]. Vital signs and laboratory
data, including prolactin and hemoglobin A1c (HbA1c),
were checked at each assessment point. At every visit, ad-
verse events were carefully checked via spontaneous re-
ports from the patient and observation by the same
treating psychiatrist. In addition, assessment of the extra-
pyramidal symptoms using the Drug-Induced Extrapyr-
amidal Signs Scale (DIEPSS) [23] and sleep difficulty
assessment using the Athens Insomnia Scale (AIS) [24]
were done at each assessment.
Assessment of neurocognition
For the neurocognitive assessment, we adopted the Brief
Assessment of Cognition in Schizophrenia (BACS) [25,26],
which is a brief set of tests designed to derive a composite
score for neurocognitive functioning. The score from each
test of the BACS was standardized by creating z score
whereby the mean score of the healthy subjects were set to
zero and the standard deviation was set to one. The com-
posite score was then calculated by averaging all of the z
scores of the six primary measures. The mean and stand-
ard deviation of normal Japanese individuals were derived
from the published data of 709 normal Japanese subjects
[27]. To compensate for practical effects, we recruited nor-
mal subjects and implemented the BACS four times at the
same time interval as our schizophrenia subjects (baseline
and 3, 6, and 12 months after). For the control group, ten
subjects (five females) with no history of a DSM-IV
Axis I disorder were recruited from the community.
None of the control subjects had a neurological dis-
order or a first-degree relative with a DSM-IV Axis I
disorder, nor were any of them receiving psychotropic
medications. The mean age of the participants was
27.3 (SD = 2.3) years, and the duration of education
was 18.2 (1.5) years. Both of which were significantly
different from those of our schizophrenia subjects (age
50.7 (14.3), Wilcoxon test, P < 0.01; duration of education
12.9 (1.7), Wilcoxon test, P < 0.01) (Additional file 1).
Statistical analyses
We compared the baseline categorical variables using χ2 or
Fisher exact tests and examined the differences in the con-
tinuous variables among the follow-up time points using
with repeated measure analysis of variance (rANOVA).
Bonferroni correction was applied for multiple compari-
sons between each pair of subgroups. The last available as-
sessment was carried forward if the actual data were not
available (LOCF). Safety evaluations were based on all
included patients treated with the studied medication
except for three subjects who were omitted from all
analyses because of incomplete data. Data were obtained






Sex (male/female) 10/12 3/4 0.59






Reason for switching 0.60
Treatment resistant 13 3
Treatment intolerant 5 3
Resistant and intolerant 4 1
Education, year
Subject 12.9 (1.8) 13.0 (1.0) 0.59
Father 12.3 (2.6) 10.5 (1.9) 0.28












Values are expressed as the mean (SD) unless otherwise indicated.
aDifferences in two groups with P values calculated by the Wilcoxon test or
the χ2 test (sex, clinical subtype, reason for switching, and
previous antipsychotics).
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for weight, HbA1c, GAF, and AIS; 25 subjects for
BACS; 24 subjects for prolactin and DAI-30; and 24
subjects for JSQLS.
For the neurocognitive study, the baseline measures of
the demographic data and the BACS z scores were com-
pared between the schizophrenic subjects and the con-
trol group specifically recruited for the practice effect
using the Wilcoxon test for continuous variables and the
Fisher’s exact test for categorical variables. In the next
step, analysis of covariance (ANCOVA) was used to detect
the group (schizophrenia and normal subjects) x time
(baseline to 3, 6, and 12 months) interaction, as well as
the interaction as a factor of the baseline pretest score
or age.
All comparison tests were two-tailed. Differences among
groups were considered statistically significant if the P value
was less than 0.05.
Results
Patient description and baseline demographics, severity
of illness, and previous treatments
A total of 32 patients signed the informed consent
forms, but three of them were omitted from the ana-
lysis including safety analysis because of incomplete data
and the remaining 29 patients were included. Seventeen
subjects entered the study due to treatment resistance, six
entered due to treatment intolerance, and six were re-
cruited due to both treatment resistance and treatment
intolerance. The subjects were medicated as follows:
risperidone (n.16); haloperidol (n.8); olanzapine (n.3);
aripiprazole (n.1); blonanserin (n.1). The mean chlor-
promazine equivalent dosage for the previous treat-
ment was 438.0 (s.d. 242.3) mg/day.
Twenty-seven subjects completed the 3-month evalu-
ation, 26 finished the 6-month assessment, and 22 reached
the 12-month mark. Three patients dropped out because
of worsening of psychotic symptoms, two dropped out be-
cause of somnolence, and one dropped out because of
alopecia. Another one subject was discontinued due to
a change of address. The last observation was carried
forward for the analysis of patients who were dropped
from the study. The baseline demographic data, the se-
verity of illness, and previous treatment are shown in
Table 1. There were no significant differences in the
demographic and clinical profiles between the subjects
who completed the study and those who did not.
Efficacy
The patients who switched to quetiapine had significant
improvements in all subscores of the PANSS, the JSQLS
score for symptoms and side effects, and GAF (Table 2).
AIS score also improved significantly. The reason to
switch (resistant vs intolerant) did not affect the changeof PANSS positive (repeated ANOVA, effect of times x
reason to switch, F(3,19) = 1.14, P = 0.36) and negative
scores (repeated ANOVA, effect of times x reason to
switch, F(3,19) = 1.00, P = 0.41).
Safety and tolerability
Quetiapine significantly improved the DIEPSS score and
the prolactin level throughout the study period. (Table 2)
The weights and HbA1c did not increase during the
treatment with quetiapine. The amelioration of the ad-
verse events was also shown in the improvement of the
symptoms and side effects subscale of the JSQLS. Three
patients dropped out because of worsening of psychotic
symptoms. Two additional patients were dropped out
from the study because of somnolence. The DAI-30
score showed a trend for increase but did not reached
statistical significance (P = 0.07).
Changes in the neurocognitive battery test
Additional file 1 summarizes the demographic character-
istics and BACS scores at the baseline of the patients
and controls. There were significant differences in the
age, the duration of education, and all the scores on the
Table 2 Changes in clinical measurements
Baseline 3 months 6 months 12 months Repeated ANOVAa
F P
Average dose of QTP (mg/day) - 379.6 (231.7) 418.5 (243.4) 438.6 (261.7) - -
Weight (kg) 56.9 (12.2) 57.6 (12.4) 57.0 (11.6) 57.3 (10.7) F(3,75) = 0.44 0.64
HbA1C (%) 4.97 (0.32) 4.95 (0.37) 4.98 (0.35) 4.89 (0.32) F(3,75) = 1.32 0.28
PANSS
Positive symptoms 18.1 (4.7) 15.7 (4.8) 16.4 (54.2) 15.3 (4.1) F(3,81) = 5.35 <0.01
Negative symptoms 23.5 (5.2) 21.5 (5.5) 20.8 (6.2) 19.6 (6.5) F(3,81) = 11.40 <0.01
General pathological symptoms 39.8 (10.2) 36.8 (9.3) 36.8 (10.5) 34.7 (10.1) F(3,81) = 7.83 <0.01
GAF 42.4 (14.7) 50.3 (12.7) 51.7 (14.0) 51.6 (15.6) F(3,75) = 10.54 <0.01
AIS 5.0 (3.1) 4.9 (3.6) 3.5 (2.9) 3.7 (3.0) F(3,75) = 3.35 0.04
DIEPSS 6.4 (4.9) 3.9 (3.2) 3.1 (2.8) 3.0 (2.9) F(3,81) = 13.74 <0.01
Prolactin (ng/ml) 33.1 (26.2) 17.8 (20.8) 21.0 (27.0) 19.9 (28.0) F(3,69) = 4.04 0.02
DAI-30 −8.6 (3.2) −5.0 (7.1) −6.8 (5.2) −6.3 (5.9) F(3,69) = 2.78 0.07
JSQLS
Psychosocial 37.9 (13.5) 37.2 (11.7) 35.0 (11.6) 35.3 (12.2) F(3,66) = 1.42 0.25
Motivation 21.6 (2.9) 20.2 (4.0) 19.9 (2.8) 19.7 (3.6) F(3,66) = 2.23 0.11
Symptoms and side effects 16.7 (4.5) 14.7 (4.3) 14.4 (4.6) 14.9 (5.4) F(3,66) = 3.20 <0.05
Values are expressed as the mean (SD) unless otherwise indicated.
aPost hoc analyses with Bonferroni correction: (pairs of comparison not specified here were all with P values of >0.05, BL baseline, 3 m 3 months, 6 m 6 months,
12 m 12 months) PANSS positive symptoms: BL vs 12 m (P = 0.02); PANSS negative symptoms: BL vs 3 m (P = 0.01), BL vs 6 m(P = 0.03), BL vs 12 m (P < 0.01), 3 m
vs 12 m (P = 0.02); PANSS general pathological symptoms: BL vs 3 m (P = 0.02), BL vs 12 m (P < 0.01), 6 m vs 12 m (P = 0.03); GAF: BL vs 3 m (P < 0.01), BL vs 6 m
(P < 0.01), BL vs 12 m (P < 0.01); Athens Insomnia Scale: BL vs 6 m (P = 0.03); DIEPSS: BL vs 3 m (P < 0.01), BL vs 6 m (P < 0.01), BL vs 12 m (P < 0.01); prolactin: BL vs
3 m (P < 0.01), BL vs 12 m (P < 0.01); JSQLS symptoms and side effects: BL vs 3 m (P = 0.03).
HbA1c hemoglobin A1c, PANSS Positive and Negative Symptoms Scale, GAF Global Assessment of Functioning, AIS Athens Insomnia Scale, DIEPSS Drug-Induced
Extrapyramidal Signs Scale, DAI-30 Drug Attitude Inventory with 30 dichotomous items, JSQLS Schizophrenia Quality of Life Scale Japanese version.
Figure 1 The change of the scores of Brief Assessment of
Cognition in Schizophrenia (BACS). Results of each test were
standardized by setting the mean of the normal dataset to zero and
the SD to one. BL baseline, 3 m 3 months, 6 m 6 months, 12 m
12 months. *P < 0.05, **P < 0.01, repeat ANOVA. Post hoc analyses
were conducted with Bonferroni correction. Verbal memory: BL vs
6 m, P = 0.04, BL vs 12 m, P < 0.01; digit sequencing task: BL vs 12 m,
P = 0.01; word fluency: BL vs 6 m, P = 0.03, BL vs 12 m, P < 0.01;
symbol coding: BL vs 3 m, P = 0.02, BL vs 12 m, P < 0.01; Tower of
London: BL vs 6 m, P = 0.01, BL vs 12 m, P < 0.01; composite score:
BL vs 3 m, P = 0.43, BL vs 6 m, P < 0.01, BL vs 12 m, P < 0.01, 3 m vs
12 m, P = 0.04. P > 0.05 for all other paired comparisons.
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subjects ranged from −2.78 (token motor test) to −1.18
(word fluency), which were similar to previous studies.
In the next step, ANCOVA was implemented to detect
the group (schizophrenia and normal subjects) x time
(baseline to 3, 6, and 12 months) interaction, as well as
the interaction as a factor of the baseline pretest score
or age (Figure 1, Additional file 2). In this analysis, we
found a significant effect of time on verbal memory, the
token motor test, and the composite score. Furthermore,
we found a significant interaction of time x group in the
verbal memory test. Post hoc analyses using ANOVA
with Bonferroni correction revealed that both normal
subject group [F(3,27) = 3.67, (P = 0.03)] and schizophre-
nia subject group [F(3, 72) = 4.30, (P < 0.01)] showed sig-
nificant increase of the score. The effect size (Cohen’s d)
of the improvement between baseline and 12 months
was 0.21 for normal subjects and 0.64 for schizophrenia
subjects, which showed that the improvement of verbal
memory by quetiapine therapy was greater than the
practice effect of normal subjects.
Discussion
This study was a prospective, 1-year open-label study to
evaluate the long-term effect of quetiapine on the clinical
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schizophrenia who had an inadequate response or who
poorly tolerated their previous antipsychotic medication.
The total drop-out rate was 24.1% (7/29), which is consist-
ent with prior open-label study [14,18]. Statistically signifi-
cant improvements were observed on all subscales of the
PANSS, the GAF, and the symptoms and side effects sub-
scale of the JSQLS, the DIEPSS, the AIS, and the prolactin
level, and nearly significant improvements were observed
in the DAI-30. Regarding the neurocognitive performance,
quetiapine therapy showed significant improvement in
verbal memory test even after controlling the practice ef-
fect. Overall, as expected, quetiapine showed long-term
improvement in broad symptom dimensions including
negative and neurocognitive symptoms with good toler-
ability. To the best of our knowledge, this is the first study,
albeit preliminary, showing long-term neurocognitive ben-
efits of switching to quetiapine in patients that showed in-
adequate response to prior antipsychotics.
In this trial, the patients who switched to quetiapine
had significant improvements of broad range of symp-
toms as demonstrated by the changes in the all sub-
scores of the PANSS, the JSQLS score for symptoms and
side effects, and GAF. A clinical benefit was also shown
for insomnia reflected by the improvement of AIS score.
In concordance with our hypothesis, negative symp-
toms were ameliorated in addition to the positive and
general pathological symptoms. In the study by Larmo
and his colleagues, when quetiapine was switched from
risperidone, the improvement of the negative and gen-
eral psychopathological symptoms was more prominent
than that of the positive symptom [14]. In our study,
most patients had been treated by haloperidol (27.6%) or
risperidone (51.7%) before registration for our study. By
replacing these treatments with quetiapine, which has a
much weaker affinity for the D2 receptor, we successfully
achieved amelioration of the negative symptoms. This is
consistent with the previous report which showed that
higher postsynaptic D2 blockade could mimic certain
negative symptoms [28].
In accordance with our other hypothesis, quetiapine
therapy also showed significant improvement in verbal
memory, even after controlling for practice effects. This
improvement continued for a year. Impaired verbal mem-
ory is associated with poor community functioning and a
poor response to psychosocial rehabilitation programs
[29], and the improvement of verbal memory is particu-
larly important for the cognitive remediation strategy [30].
However, we should evaluate this result with maximum
caution because 1) a switch design study is not suitable
for comparing the cognitive remediation effects of an-
tipsychotics [8], 2) the improvement of cognitive dis-
turbance may be due to the improvement of clinical
symptoms and/or extrapyramidal side effects in part[31], and 3) there is a possibility of ceiling effect in the
data of normal control.
About the tolerability, switching to quetiapine induced
a decrease in the prolactin levels, improvement of the
extrapyramidal symptoms, and a decrease in the use of
anticholinergics. At the baseline and at each time point,
the number of the subjects who were prescribed with
anticholinergics and the mean daily biperiden equivalent
dose changed as follows: baseline [n.13, dose. 3.7 (SD =
2.2) mg/day]; 3 months [n.10, dose 3.3 (2.1) mg/day];
6 months [n.7, dose 3.7 (2.4) mg/day]; 12 months [n.7,
dose 3.7 (2.4) mg/day]. Weight gain and glucose intoler-
ance were not apparent in our patients. Somnolence and
worsening of the psychotic symptoms were noticeable
adverse events, and this finding is consistent with previ-
ous studies [11,13-15]. However, the sedative effect of
quetiapine improved the insomnia of our subjects, and
this was reflected in the improvement of the AIS score.
Tolerability findings were consistent with the trending
improvement in DAI, although it did not reach statistical
significance level. This may be due to the small sample
size.
There are several limitations in our study. First, the
small sample size of our study may limit the ability to
detect moderate to small changes. As a consequence of
the small sample size, we could not perform subgroup
analyses, such as an analysis according to the prior anti-
psychotics. Second, because this was an open-label study
with no control group except for the neurocognitive bat-
tery test, our study was prone to selection and observer
bias. There was no indication of spontaneous recovery.
Third, our normal control for the neurocognitive battery
test was much younger and much longer educated than
our schizophrenia subjects, and the score of the neuro-
cognitive battery test was higher in the normal control
group, though we used these factors as covariants in the
statistical analysis. A younger age results in a better
practice effect in general, and this age difference had
never shown a favorable effect in the schizophrenia pa-
tient group. However, there is a possibility of ceiling effect
in the score of our normal subject and the improvement
of neurocognitive battery test in this study should be
examined carefully, as we discussed above. Fourth, we
did not have an objective measurement of treatment
adherence, although the results of the DAI-30 indir-
ectly suggested that their adherence was good through-
out the study period.
Conclusion
In this open-label, single-arm study of 29 patients, we
found that quetiapine improved both the clinical symptoms
and the neurocognitive impairment in chronic schizophre-
nia patients who switched from other antipsychotics be-
cause of inadequate response. While the frequency and
Hashimoto et al. Annals of General Psychiatry  (2015) 14:1 Page 7 of 8importance of antipsychotic are switching in patients with
schizophrenia, there is insufficient evidence with regard to
switching strategy. We hope that further studies seeking
better antipsychotic switching strategies in clinical practice
will be continued.
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Additional file 2: Change of the BACS z scores and the results of
ANCOVA controlled for age.
Abbreviations
AIS: Athens Insomnia Scale; ANCOVA: analysis of covariance; BACS: brief
assessment of cognition in schizophrenia; CGI: Clinical Global Impressions
Scale; DAI-30: Drug Attitude Inventory with 30 dichotomous items;
DIEPSS: Drug-Induced Extrapyramidal Signs Scale; HbA1c: hemoglobin A1c;
JSQLS: Schizophrenia Quality of Life Scale Japanese version; LOCF: last
observation carried forward; PANSSs: Positive and Negative Syndrome Scales;
rANOVA: repeated measure analysis of variance.
Competing interests
KI and NH received research grants from Astellas Pharma. For the remaining
authors, none were declared.
Authors’ contributions
KI and NH contributed substantially to the design and analysis of the study,
as well as to development and critical revision of the manuscript. AT
contributed substantially to the assessment and data analysis of BACS. TK
contributed substantially to the critical revision of the manuscript. MH, SM,
NN, HS, YS, KU, and NT contributed substantially to the recruitment and
assessment of the subjects. All authors read and approved the final
manuscript.
Acknowledgement
The authors are grateful to Dr Yuki Omiya, Dr Tomoo Ogawa, Dr Susumu
Oshibe, Dr Naomichi Kaji, Dr Yukie Kumazawa, Dr Kuniko Terae, Dr Shigetaka
Nakae, and Dr Yuji Honma who entry the subjects to this study. We thank
Fumiko Hoeft, MD, PhD, for editorial assistance. Their dedication made this
study possible.
Author details
1Department of Psychiatry, Hokkaido University Graduate School of Medicine,
060-8638, North 15, West 7, Kita-ku, Sapporo, Japan. 2Child and Adolescent
Psychiatry, Department of Psychiatry University of California, 401 Parnassus
Ave, Box 0984-F, San Francisco, CA 94143, USA. 3Honda Memorial Hospital,
061-1364, 619-1, Shimoshimamatsu Eniwa, Hokkaido, Japan. 4Teine Hospital,
006-0816, 8-15, Maeda 6-jo 13-chome, Teine-ku, Sapporo, Japan. 5Sapporo
Hanazono Hospital, 064-0915, 1-30, South 15, West 15, Chuo-ku, Sapporo,
Japan. 6San-ai Hospital, 059-0463, 24-12, Nakanoboribetsu-cho Noboribetsu,
Hokkaido, Japan. 7Psychiatric Medical Center, Sapporo City General Hospital,
060-0011 1-1, North 11, West 13, Chuo-ku, Sapporo, Japan. 8Department of
Psychiatry, Hakodate Watanabe Hospital, 042-0932, 1-31-1, Yunokawa Hakodate,
Hokkaido, Japan. 9Oyachi Hospital, 004-0041, 7-10, Oyachi-higashi 5-chome,
Atsubetsu, Sapporo, Japan.
Received: 30 June 2014 Accepted: 17 December 2014
References
1. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are
second-generation antipsychotic drugs? A meta-analysis of placebo-controlled
trials. Mol Psychiatry. 2009;14:429–47.
2. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO,
et al. Clinical Antipsychotic Trials of Intervention Effectiveness, Investigators
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
N Engl J Med. 2005;353:1209–23.3. Dold M, Leucht S. Pharmacotherapy of treatment-resistant schizophrenia: a
clinical perspective. Evid Based Ment Health. 2014;17:33–7.
4. Weiden PJ, Young AH, Buckley PF. The art and science of switching of
antipsychotic medications, part 1. J Clin Psychiatry. 2006;67:e15.
5. Riedel M, Muller N, Strassnig M, Spellmann I, Severus E, Moller HJ.
Quetiapine in the treatment of schizophrenia and related disorders.
Neuropsychiatr Dis Treat. 2007;3:219–35.
6. da Silva AF, Figee M, van Amelsvoort T, Veltman D, de Haan L. The revised
dopamine hypothesis of schizophrenia: evidence from pharmacological MRI
studies with atypical antipsychotic medication. Psychopharmacol Bull.
2008;41:121–32.
7. Kirkpatrick B, Fenton WS, Carpenter Jr WT, Marder SR. The NIMH-MATRICS
consensus statement on negative symptoms. Schizophr Bull.
2006;32:214–9.
8. Hill SK, Bishop JR, Palumbo D, Sweeney JA. Effect of second-generation
antipsychotics on cognition: current issues and future challenges. Expert
Rev Neurother. 2010;10:43–57.
9. Peuskens J, Trivedi J, Malyarov S, Brecher M, Svensson O, Miller F, et al.
Prevention of schizophrenia relapse with extended release quetiapine
fumarate dosed once daily: a randomized, placebo-controlled trial in clinically
stable patients. Psychiatry. 2007;4:34–50.
10. Liu J, Sun J, Shen X, Guo W, Zhi S, Song G, et al. Randomized controlled trial
comparing changes in serum prolactin and weight among female patients
with first-episode schizophrenia over 12 months of treatment with risperidone
or quetiapine. Shanghai Arch Psychiatry. 2014;26:88–94.
11. Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety,
efficacy, and tolerability of quetiapine and risperidone in outpatients with
schizophrenia and other psychotic disorders: the quetiapine experience
with safety and tolerability (QUEST) study. Clin Ther. 2001;23:1839–54.
12. Smeraldi E, Cavallaro R, Folnegovic-Smalc V, Bidzan L, Emin Ceylan M,
Schreiner A. Long-term remission in schizophrenia and schizoaffective
disorder: results from the risperidone long-acting injectable versus quetiapine
relapse prevention trial (ConstaTRE). Ther Adv Psychopharmacol. 2013;3:191–9.
13. Gaebel W, Schreiner A, Bergmans P, de Arce R, Rouillon F, Cordes J, et al.
Relapse prevention in schizophrenia and schizoaffective disorder with
risperidone long-acting injectable vs quetiapine: results of a long-term,
open-label, randomized clinical trial. Neuropsychopharmacology.
2010;35:2367–77.
14. Larmo I, de Nayer A, Windhager E, Lindenbauer B, Rittmannsberger H, Platz T,
et al. Efficacy and tolerability of quetiapine in patients with schizophrenia who
switched from haloperidol, olanzapine or risperidone. Hum Psychopharmacol.
2005;20:573–81.
15. Chue P, Malla A, Bouchard RH, Lessard S, Ganesan S, Stip E, et al. The long-term
clinical benefit and effectiveness of switching to once-daily quetiapine extended
release in patients with schizophrenia. Curr Med Res Opin. 2013;29:227–39.
16. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al.
Neurocognitive effects of antipsychotic medications in patients with chronic
schizophrenia in the CATIE trial. Arch Gen Psychiatry. 2007;64:633–47.
17. Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS,
et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia
and schizophreniform disorder: a randomized, open-label clinical trial
(EUFEST). Am J Psychiatry. 2009;166:675–82.
18. Guo X, Zhai J, Wei Q, Twamley EW, Jin H, Fang M, et al. Early-stage
Schizophrenia Outcome Study Investigators. Neurocognitive effects of
first- and second-generation antipsychotic drugs in early-stage schizophrenia:
a naturalistic 12-month follow-up study. Neurosci Lett. 2011;503:141–6.
19. Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, et al.
Effects of olanzapine, quetiapine, and risperidone on neurocognitive
function in early psychosis: a randomized, double-blind 52-week comparison.
Am J Psychiatry. 2007;164:1061–71.
20. Riedel M, Schennach-Wolff R, Musil R, Dehning S, Cerovecki A, Opgen-Rhein M,
et al. Neurocognition and its influencing factors in the treatment of
schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone.
Hum Psychopharmacol. 2010;25:116–25.
21. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale
(PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–76.
22. Kaneda Y, Imakura A, Fujii A, Ohmori T. Schizophrenia Quality of Life Scale:
validation of the Japanese version. Psychiatry Res. 2002;113:107–13.
23. Inada T, Beasley Jr CM, Tanaka Y, Walker DJ. Extrapyramidal symptom
profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale:
comparison with Western scales in the clinical double-blind studies of
Hashimoto et al. Annals of General Psychiatry  (2015) 14:1 Page 8 of 8schizophrenic patients treated with either olanzapine or haloperidol. Int Clin
Psychopharmacol. 2003;18:39–48.
24. Soldatos CR, Dikeos DG, Paparrigopoulos TJ. Athens Insomnia Scale:
validation of an instrument based on ICD-10 criteria. J Psychosom Res.
2000;48:555–60.
25. Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The brief
assessment of cognition in schizophrenia: reliability, sensitivity, and comparison
with a standard neurocognitive battery. Schizophr Res. 2004;68:283–97.
26. Kaneda Y, Sumiyoshi T, Keefe R, Ishimoto Y, Numata S, Ohmori T. Brief
assessment of cognition in schizophrenia: validation of the Japanese
version. Psychiatry Clin Neurosci. 2007;61:602–9.
27. Kaneda Y, Ohmori T, Okahisa Y, Sumiyoshi T, Pu S, Ueoka Y, et al.
Measurement and treatment research to improve cognition in
schizophrenia consensus cognitive battery: validation of the Japanese
version. Psychiatry Clin Neurosci. 2013;67:182–8.
28. Heinz A, Knable MB, Coppola R, Gorey JG, Jones DW, Lee KS, et al.
Psychomotor slowing, negative symptoms and dopamine receptor
availability–an IBZM SPECT study in neuroleptic-treated and drug-free
schizophrenic patients. Schizophr Res. 1998;31:19–26.
29. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional
outcome in schizophrenia: are we measuring the ‘right stuff’? Schizophr
Bull. 2000;26:119–36.
30. Hashimoto N, Matsui M, Kusumi I, Toyomaki A, Ito K, Kako Y, et al. Effect of
explicit instruction on Japanese verbal learning test in schizophrenia
patients. Psychiatry Res. 2011;188:289–90.
31. Stober G, Ben-Shachar D, Cardon M, Falkai P, Fonteh AN, Gawlik M, et al.
Schizophrenia: from the brain to peripheral markers. A consensus paper of
the WFSBP task force on biological markers. World J Biol Psychiatry.
2009;10:127–55.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
